• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health: Tech and the Measles Outbreak, Cell Therapy Coverage, Hospital Readmission

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
February 15, 2019, 4:24 PM ET

Happy Friday, readers.

An ongoing measles outbreak in the Pacific Northwest and beyond is now putting pressure on some of Silicon Valley’s biggest players, including Facebook and Google, to take action to debunk false information and conspiracy theories regarding vaccines.

California Rep. Adam Schiff on Thursday sent letters to Facebook CEO Mark Zuckerberg and Google CEO Sundar Pichai demanding information on what the companies are doing to tamp down on the proliferation of misinformation. Anti-vaccine conspiracy theories and misleading articles about vaccination have been regularly spread via the respective companies’ platforms.

“As a Member of Congress who is deeply concerned about declining vaccination rates, I am requesting additional information on the steps that you currently take to provide medically accurate information on vaccinations to your users, and to encourage you to consider additional steps you can take to address this growing problem,” wrote Schiff in his letter.

Schiff also praised the action taken by another tech giant to fight the current misinformation trend. “I was pleased to see YouTube’s recent announcement that it will no longer recommend videos that violate its community guidelines, such as conspiracy theories or medically inaccurate videos, and encourage further action to be taken related to vaccine misinformation,” he wrote.

Facebook is reportedly working on steps to try and curb this public health fiasco; Congress is slated to hold hearings on the issue in early March.

We’ll be off on Monday for the three-day weekend. Read on for the day’s news, and see you back in your inbox on Tuesday the 19th.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

DIGITAL HEALTH

The government is about to cover cell therapies. The Centers for Medicare & Medicaid Services (CMS) announced on Friday that new cell therapies from drug giants Novartis and Gilead—the first of their kind, treatments that re-engineer patients' cells to fight cancer but are also incredibly pricey—will be covered under an experimental payment plan by the public agency. The so-called CAR-T therapies would be covered under the proposed rule, which would also involve assessing whether these next-generation therapies provide the right amount of therapeutic bang for the buck (the list prices run between $373,000 and $475,000, though the government would pay a far lower price).

THE BIG PICTURE

Can a longer hospital stay be healthy? A new study from the University of Wisconsin researchers finds that leaving the hospital early (and against medical advice) can double the risk of readmission within 30 days. The study also highlights the specific conditions that are most likely to lead to an unadvised discharge—they include alcohol and substance abuse disorders, skin infections, and complications from diabetes, according to Reuters. (Reuters)

REQUIRED READING

Commentary: What the Recent—and Maybe Future—Shutdown Teaches Us About Wealth in the U.S., by Sandro Galea

Colin Kaepernick Settles Grievance Suit With the NFL, by Emily Price

Parties Line Up to Sue Trump on 'National Emergency' Declaration, by Bloomberg

An Activist Investor Takes on the Wage Gap, by Ellen McGirt

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortunenewsletters.
About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.